Abstract: A cosmetic or pharmaceutical rinse-off formulation contains 0.2% by weight to 20% by weight of a phase A; 0.1% by weight to 50% by weight of an active substance; a detergent; and the remainder being water. The phase A is a mixture of 20% by weight to 90% by weight of a surfactant mixture of isethionates, acyl lactylates and one of alkyl glutamates and alkyl glucosides and 10% by weight to 80% by weight of water, alcohol, polyol or mixtures thereof. The phase A forms multilamellar vesicles. The cosmetic or pharmaceutical rinse-off formulation is a clear product with the multilamellar vesicles of phase A having an average diameter of less than 100 nm.
Abstract: A method for making a personal care composition including homeopathic remedies and essential oils. The homeopathic remedies are selected from one or more pharmacopeias wherein the remedies are indicated for one or more biological conditions. Remedies are selected because they are indicated for the same disease condition or in certain embodiments related conditions. Once selected the remedies are diluted to a predetermined concentration and blended with essential oils. In certain embodiments a medicated cleansing bar, a soap, or a cleansing material may be selected for delivering the homeopathic remedy and the essential oils. The essential oils may be extracted from plant material using various techniques including distillation.
Abstract: The use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of Scutellaria root, Coptis root, Phellodendron bark, earthworm and poppy capsule, based on the total weight of the pharmaceutical compositions. In the sesame oil extract, each of Scutellaria root, Coptis root, Phellodendron bark, earthworm and poppy capsule is in an amount of 2 to 10% by weight of dry raw material based on the total weight of sesame oil. A medical dressing for treating diabetic ulcer and corresponding medicine box enclosing the said dressing are also provided.
Abstract: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention.
Type:
Grant
Filed:
July 24, 2009
Date of Patent:
July 3, 2012
Assignee:
Biova, L.L.C.
Inventors:
Ronald E. Strohbehn, Lisa R. Etzel, Jesse I. Figgins
Abstract: Modified red blood cells are described. In an embodiment, the modified red blood cell includes a target-binding agent. Targeted delivery of imaging agents, drugs, and peptide and protein pharmaceuticals using modified red blood cells are described. Processes for preparing the modified red blood cells, pharmaceutical and diagnostic compositions containing the same and methods of diagnosis and treatment involving the modified red blood cells are described.
Type:
Grant
Filed:
August 13, 2008
Date of Patent:
July 3, 2012
Assignee:
The Invention Science Fund I, LLC
Inventors:
Roderick A. Hyde, Muriel Y. Ishikawa, Edward K. Y. Jung, William Gates, Alois A. Langer, Eric C. Leuthardt, Royce A. Levien, Clarence T. Tegreene, Thomas A. Weaver, Charles Whitmer, Lowell L. Wood, Jr., Victoria Y. H. Wood
Abstract: The present invention is directed to satisfying the need to detect microbial contamination of food products. The described bioseparator/bioreactor coupled with an optical/electrochemical biosensor was able to specifically detect E. coli O157:H7 from 8.8×101 to 8.8×106 CFU/ml in 2.5 hours without any enrichment. Using this invention, concentrations of S. Typhimurium ranging from 8.6×102 to 8.6×106 CFU/ml in pure culture were detected in 2 hours without any enrichment. The invention may also be used for the detection of S. Seftenberg, which has the same sensitivity as S. Typhimurium. Other pathogens such as L. monocytogenes and S. Heidleberg did not interfere with the detection. The optimum inner diameter of the 25 cm long column for the detection of E. coli O157:H7 is 250 ?m.
Type:
Grant
Filed:
December 13, 2010
Date of Patent:
July 3, 2012
Assignee:
The Board of Trustees of the University of Arkansas
Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.
Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.
Abstract: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant.
Type:
Application
Filed:
February 27, 2012
Publication date:
June 21, 2012
Applicant:
DEPUY MITEK, INC.
Inventors:
Francois Binette, Joseph J. Hammer, Krish Mukhopadhyay, Joel Rosenblatt
Abstract: An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of Picrorhiza kurrooa Royle, Picrorhiza scrophularflora Pennell and Neopicrorhiza scrophula?iflora. Solvents and solvent combinations are disclosed. The composition is effective against both DNA and RNA viruses and against fungal, bacterial, parasitic and protozoal infections and diseases and also as a hepatoprotective, anti-hyperlipidemic, anti-diabetic and kidney-protective agent. Anti-bodies and vaccines for the cited diseases can be made by administration of the composition to animal or other subjects.
Type:
Application
Filed:
September 2, 2010
Publication date:
June 14, 2012
Inventors:
Munisekhar Medasani, Satyasayee Babu Divi
Abstract: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention.
Type:
Grant
Filed:
October 18, 2010
Date of Patent:
June 12, 2012
Assignee:
Biova, L.L.C.
Inventors:
Ronald E. Strohbehn, Lisa R. Etzel, Jesse Figgins
Abstract: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention.
Type:
Grant
Filed:
October 17, 2008
Date of Patent:
June 12, 2012
Assignee:
Biova, L.L.C.
Inventors:
Ronald E. Strohbehn, Lisa R. Etzel, Jesse Figgins
Abstract: The invention provides compositions of vaporized stem cell derivatives and methods for their use and manufacture in the treatment of skin conditions and other therapeutic applications. Stem cell derivatives comprising vaporized stem cells, stem cell factors and/or stem cell microvesicles are disclosed and contemplated as being within the scope of the invention. The invention finds use in medical, rejuvenative and cosmetic applications.
Abstract: The present invention is directed to methods of inducing spatial organization of cells an in vitro culture system using ultrasound technology. The invention is further directed to methods of inducing extracellular matrix remodeling and neovessel formation in an in vitro culture system and generating vascularized engineered tissue constructs using ultrasound technology.
Abstract: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.
Type:
Grant
Filed:
June 9, 2009
Date of Patent:
June 5, 2012
Assignee:
New York Medical College
Inventors:
Toru Hosoda, Piero Anversa, Annarosa Leri, Jan Kajstura
Abstract: Provided herein are processes of detecting and quantifying the number of polymer end groups in a sample. In particular instances provided herein are processes of detecting.
Type:
Grant
Filed:
December 31, 2009
Date of Patent:
May 22, 2012
Assignee:
Zacharon Pharmaceuticals, Inc.
Inventors:
Brett E. Crawford, Jillian R Brown, Charles A. Glass
Abstract: Three-dimensional extracellular matrices lacking synthetic scaffolds are provided. Methods of making the three-dimensional extracellular matrices and methods of using the three-dimensional extracellular matrices are also provided.
Type:
Application
Filed:
April 22, 2009
Publication date:
May 17, 2012
Applicant:
UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventors:
Patrick A. Tresco, Jeffrey Collins Wolchok
Abstract: A solubilized protein composition is obtained from avian eggshell membrane without the use of proteolytic enzymes or cross-linking agents. The composition is essentially odor-free, has an ash content of less than 10% by weight of the composition and a protein content of at least 90% by weight of the composition including a mixture of solubilized proteins such as Type I collagen. Type V collagen. Type X collagen, elastin, lysozyme, ovotransferrin, desmosine, and/or B-N-acetylglucosaminidase, wherein the solubilized proteins are undenatured and retain biological activity.
Type:
Grant
Filed:
October 18, 2010
Date of Patent:
May 8, 2012
Assignee:
Biova, L.L.C.
Inventors:
Ronald E. Strohbehn, Lisa R. Etzel, Jesse Figgins
Abstract: A method of determining a concentration of analytes of interest in a sample reaction mixture is disclosed. The method can include measuring intensities of the polarized fluorescence of at least one comparative reaction mixture containing different, known amounts of the analytes of interest, and measuring the intensities of the polarized fluorescence of a sample reaction mixture. The method can also include determining the preliminary concentrations of the analytes of interest in the sample reaction mixture by comparing the measured intensities of the sample reaction mixtures at various time points. The margin of error for the preliminary concentration of the analytes of interest in the sample can be determined at the various time points. Finally, the concentration of the analytes of interest in the sample reaction mixture can be determined by comparing the preliminary concentrations and the respective margin of error at the given time points.
Type:
Grant
Filed:
July 15, 2008
Date of Patent:
May 8, 2012
Assignee:
Aokin AG
Inventors:
Frank Mallwitz, Ursula Dahmen-Levison, Derek Levison, Stuart Levison
Abstract: A diagnostic test kit for detecting an analyte residing in a test sample is provided. The kit employs a lateral flow device that contains a membrane. A metering channel is formed in the membrane that is capable of delivering a controlled volume of the test sample to a detection zone upon initiation of the assay. Such a metering channel is particularly effective for embodiments in which the test sample has a relatively low volume, such as less than about 100 microliters, in some embodiments from about 0.5 to about 25 microliters, and in some embodiments, from about 1 to about 10 microliters. For example, whole blood drops obtained from patients with a lancet typically have a volume of less than about 3 microliters. Despite their low volume, the present inventors have discovered that the blood drops may still be accurately analyzed for the presence of an analyte using lateral flow detection techniques.
Type:
Grant
Filed:
August 31, 2010
Date of Patent:
May 8, 2012
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Kaiyuan Yang, Ning Wei, Shawn Ray Feaster
Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts.
Abstract: The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.
Type:
Application
Filed:
March 8, 2010
Publication date:
April 26, 2012
Applicant:
UNIVERSITE PARIS DESCARTES
Inventors:
Bruno Gogly, Antoine Lafont, Bernard Coulomb, Jean-Jacques Lataillade
Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
Type:
Grant
Filed:
July 12, 2011
Date of Patent:
April 24, 2012
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
John O'Connor, Steven Birken, Galina Kovalevskaya
Abstract: The present technology provides compositions of vesicles, uses of vesicles, and methods relating to vesicles. For example, provided herein are vesicles derived from stem cells for use in regenerative therapies.
Type:
Application
Filed:
October 18, 2011
Publication date:
April 19, 2012
Applicant:
NORTHWESTERN UNIVERSITY
Inventors:
Susmita Sahoo, Douglas W. Losordo, David E. Zembower
Abstract: A porous, self-sustaining body useful as a scaffold for bone grafting is provided. The scaffold comprises a carbonaceous matrix comprising a continuous phase having a surface and defining a plurality of open spaces throughout the matrix. The internal and external surfaces of the matrix are coated with a layer or film selected from the group consisting of osteogenic materials, therapeutic agents, and combinations thereof. The porous body comprises organic materials and is substantially free of metals. Methods of making and using the porous self-sustaining body are also provided, along with kits for facilitating the same.
Abstract: A method for immobilizing glycoprotein is disclosed. A surface is provided. Next, a boronic acid is contacted to the surface. The boronic acid is represented as Y—R—B—(OH)2 and includes a boronic acid group (B—(OH)2), a linker R, and a functional group Y, in which the boronic acid is bonded to the surface via the functional group Y. A glycoprotein is contacted to the boronic acid, wherein two spatially adjacent hydroxyl groups of a carbohydrate chain form a boronate ester with the boronic acid group of the boronic acid to immobilize the glycoprotein. The goal of site-specific and covalent protein immobilization without interfering the binding affinity of an antibody to antigen may be thus achieved with the reaction of boronic acid and the carbohydrate chain of Fc region.
Abstract: A medical device for safe and sure delivery of drugs to the lesion and a method for production thereof. The medical device has at least part of its surface in contact with the lumen wall tissue of the living body coated with a drug releasing layer containing a drug and a phospholipid, the drug and the phospholipid forming a solid dispersion.
Abstract: The present invention relates to methods of increasing the selenium content in beef by feeding special enriched diets, methods of improving human immune function, such as providing anticancer benefits. The present invention further provides methods for improving the quality of beef meat through a special enhanced diet, wherein organic selenium, copper, zinc and manganese replace all inorganic and metallic forms.
Abstract: There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.
Type:
Application
Filed:
March 29, 2010
Publication date:
March 22, 2012
Inventors:
Michel Maurice Jacques Lazdunski, Catherine Louise Heurteaux, David Picard
Abstract: Provided is a method of producing a dry earthworm powder without deterioration in useful pharmacological action, by removing dirt on the skin of earthworms while allowing the earthworms to excrete the digest remaining in the digestive tracts efficiently without weakening the earthworms, which comprises the steps of: standing living earthworms under light for 10 to 50 hours, removing the dirt formed on the skin thereof, adding an organic acid to the living earthworms, diluting the acid rapidly with addition of water, adjusting the pH of the aqueous acidic solution to 2 to 5, standing the earthworm mixture for 3 to 180 minutes under the pH condition, washing the earthworms with water, grinding the earthworms into a homogenate, freezing the homogenate at ?18° C. to ?35° C., keeping the frozen homogenate for 20 to 240 hours, and freeze-drying and degassing the frozen homogenate under vacuum simultaneously.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
March 20, 2012
Assignee:
Well Stone Co.
Inventors:
Yoichi Ishii, Hiroyuki Sumi, Etsuo Yoshida
Abstract: Provided herein are methods of producing a meniscus scaffold to remove material and increase the pore size and porosity therein. In some embodiments, methods include seeding the tissue with allogeneic or autogeneic cells. Bioscaffolds produced by the processes described herein are also provided, as are methods of treating a subject in need of a bioscaffold implant.
Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
Type:
Application
Filed:
April 12, 2010
Publication date:
March 1, 2012
Inventors:
Etzer Darout, Michael Paul DeNinno, Kentaro Futatsugi, Cristiano Ruch Werneck Guimaraes, Bruce Allen Lefker, Vincent Mascitti, Kim Francis McClure, Michael John Munchhof, Ralph Pelton Robinson, JR.
Abstract: The present invention is a peritoneal dialysis and hemodialysis hybrid-remedy planning method using an index that is shared by both peritoneal dialysis and hemodialysis and indicates an effect of dialysis. To be specific, the index is M/C(0)/VB, which is obtained by dividing a ratio M/C(0)—where M is a removal amount of a solute for a fixed time period, and C(0) is a concentration of the solute in blood before the dialysis—by a patient's body fluid volume, VB. The present invention is capable of representing the dialysis effect of PD and HD as an integrated sum, and achieving concise and explicit PD and HD hybrid-remedy planning.
Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
Type:
Grant
Filed:
April 18, 2008
Date of Patent:
February 21, 2012
Assignee:
Tethys Bioscience, Inc.
Inventors:
Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
Abstract: The present invention relates to an assay which can be used on nasal secretions. The assay is used to determine the cause of nasal secretions, for example whether the secretions are due to an allergic reaction or a non-allergic reaction.
Abstract: The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable.
Abstract: A range of infant food products wherein each product in the range includes minimal levels of undesired by-products produced during processing as indicated by less than about 15 micrograms furan per kg food product.
Type:
Application
Filed:
September 5, 2008
Publication date:
January 12, 2012
Inventors:
Frank Weber, Simon Hutschenreuther, Nadine Kalb, Martinas Kuslys
Abstract: The present invention is a peritoneal dialysis and hemodialysis hybrid-remedy planning method using an index that is shared by both peritoneal dialysis and hemodialysis and indicates an effect of dialysis. To be specific, the index is M/C(0)/VB, which is obtained by dividing a ratio M/C(0)—where M is a removal amount of a solute for a fixed time period, and C(0) is a concentration of the solute in blood before the dialysis—by a patient's body fluid volume, VB. The present invention is capable of representing the dialysis effect of PD and HD as an integrated sum, achieving concise and explicit PD and HD hybrid-remedy planning.
Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.
Abstract: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.
Abstract: The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.
Abstract: Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the extracellular matrix. Additionally or alternatively, one of the multiple cell types can be delivered to a site in the body via the endogenously produced extracellular matrix components to achieve various therapeutic benefits.
Type:
Application
Filed:
January 14, 2011
Publication date:
December 1, 2011
Inventors:
Dolores Baksh, Xianyan Wang, Matthew Q. Wong, Lan Cao, Parid Sava, Thomas Bollenbach, Esin Yesilalan
Abstract: The present invention relates to analyte detection test systems, including test systems for the oral detection of analytes in saliva. The present invention also provides compositions and methods for storing multiple assay tests and compositions and methods for measuring the concentration of analytes in a sample.
Type:
Grant
Filed:
April 16, 2010
Date of Patent:
November 29, 2011
Assignee:
N2ITIVE1 Innovations
Inventors:
Anthony Toranto, Evan Singer, Brett Miller
Abstract: The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.
Type:
Grant
Filed:
November 23, 2009
Date of Patent:
November 22, 2011
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Georg Hess, Hendrik Huedig, Rosemarie Kientsch-Engel, Dietmar Zdunek
Abstract: A method is described for enriching procaryotic DNA, said method including the steps of contacting at least one procaryotic DNA with at least one protein or polypeptide which is capable of specifically binding to non-methylated CpG motifs, and separating the protein/polypeptide-DNA complex. Moreover, the application relates to a kit for carrying out said method.
Type:
Grant
Filed:
August 8, 2003
Date of Patent:
November 22, 2011
Assignee:
SIRS-Lab GmbH
Inventors:
Karl-Hermann Schmidt, Eberhard Straube, Stefan Russwurm
Abstract: Antioxidant compositions for the stabilization of fat sources against oxidation, stabilized fat source compositions, and methods of stabilizing fat sources against oxidation are described. In particular, an antioxidant emulsion that includes quercetin in addition to at least one other ingredient and a lipid carrier is described.
Abstract: The invention relates pharmaceutical/dietary supplement/food ingredient(s) selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Sphaeranthus indicus and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Garcinia mangostana. The ingredients and the composition(s) can be used for the control, prevention and treatment of obesity, metabolic syndrome, diabetes and other metabolic disorders, and also to regulate energy expenditure, prevention of atherosclerotic plaques in coronary artery and abdominal aorta, increase insulin sensitivity, prove glucose tolerance, lower triglyceride levels and balance glucose levels in mammals.
Abstract: The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a composition for the treatment and/or prevention of these diseases.
Type:
Grant
Filed:
December 18, 2006
Date of Patent:
November 15, 2011
Assignee:
Neptune Technologies & Bioressources Inc.
Abstract: The present invention relates generally to detection of occult blood. In particular, the present invention provides a device and methods for the simultaneous detection of hemoglobin and transferrin in fecal samples, which permit a more sensitive diagnosis of occult blood in fecal sample and a differential diagnosis of bleeding of the upper GI tract versus the lower GI tract.